300 results
8-K
EX-99.1
CRDF
Cardiff Oncology Inc
4 Dec 14
Trovagene Announces Presentation of Clinical Data at the 56th Annual American Society of Hematology Meeting
12:00am
are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward … to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy
8-K
CRDF
Cardiff Oncology Inc
3 Oct 14
Regulation FD Disclosure
12:00am
in this current report on Form 8-K are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may … to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation
8-K
EX-99.1
CRDF
Cardiff Oncology Inc
6 Feb 15
Trovagene, Inc. Announces Pricing of Public Offering of Common Stock
12:00am
are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use … to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy
8-K
EX-99.1
CRDF
Cardiff Oncology Inc
21 Jan 15
Other Events
12:00am
Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated … ; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier
8-K
EX-99.1
CRDF
Cardiff Oncology Inc
21 Oct 13
Other Events
12:00am
within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words … concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process
8-K
EX-99.2
0k75qd0k
5 Feb 15
Other Events
12:00am
8-K
EX-99.1
o0e79i1lqfcuup3n3u
7 Dec 20
Cardiff Oncology Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML
1:22pm
8-K
EX-99.1
ms44o9ov4xb6tejz2k9
26 Jan 15
Trovagene’s Chief Scientific Officer to Present Precision Cancer MonitoringSM Platform Overview at the Personalized Medicine World Conference
12:00am
8-K
EX-99.1
w4mmgqngnd 6t6un
24 Jul 13
Trovagene Announces Issuance of Broad MicroRNA Patent
12:00am
8-K
EX-99.1
8tl7d9wkmr8nie5h58
6 Sep 13
Other Events
12:00am
8-K
EX-99.1
egn 8nynl4rlzic4
1 Jul 14
Trovagene Secures $15 Million in Debt Financing From Silicon Valley Bank and Oxford Finance
12:00am
8-K
EX-99.1
mfok wmq6
25 Aug 21
Other Events
1:23pm
8-K
EX-99.1
tc5qd
27 Dec 12
Regulation FD Disclosure
12:00am
8-K
EX-99.1
scb71h3g7jahenp
27 Mar 13
Trovagene Launches Urine-Based HPV Test
12:00am
8-K
EX-99.1
2l98pd3dhcaxu89irhf
8 Aug 14
Trovagene, Inc. Announces Second Quarter 2014 Financial Results
12:00am
8-K
EX-99.1
w12ss4l39ejxujkzw6
28 Nov 12
Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
12:00am
8-K
EX-99.1
pbymv w8ik2ez6
28 May 14
Other Events
12:00am
8-K
EX-4.1
ra15pfv
6 Jan 12
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
yjedlrtao47r r41za
30 Oct 13
Dr. Paul Billings Joins Trovagene’s Board of Directors
12:00am
8-K
EX-99.1
s6yvgjfnd
8 Apr 14
Other Events
12:00am